Ratings changes for IREN, Affirm, Ultragenyx Pharmaceutical, Affirm, Marvell Technology, IREN, IREN and more...

August 28th, 2026

Unsubscribe
 
 
MarketBeat Daily RatingsMy Portfolio
Text "MarketBeat" to  68285 for free, real-time alerts on your watchlist stocks.  Get Free Alerts

Today's Top Stories

Boeing's $131B F-15 Win: Mach 1 Momentum or Just Altitude?

Boeing's $131B F-15 Win: Mach 1 Momentum or Just Altitude?

By Jeffrey Neal Johnson

BWX Technologies’ Army Reactor Win Could Redraw Its Nuclear Growth Story

BWX Technologies’ Army Reactor Win Could Redraw Its Nuclear Growth Story

By Jeffrey Neal Johnson

Meta’s $18 Billion Settlement May Be a Win for Investors

Meta’s $18 Billion Settlement May Be a Win for Investors

By Leo Miller

Wall Street’s quietly buying these 3 AI infrastructure plays

Sponsored · Partner Content

Wall Street’s quietly buying these 3 AI infrastructure plays

Hedge funds are rotating out of AI hype and into the hardware layer powering it. New research identifies three profitable U.S. infrastructure companies leading this shift. One just posted 76% year-over-year data-center growth. Another holds a $12 billion backlog from global hyperscalers. A third is generating 59%+ gross margins on next-gen chips…

Access the full analysis, price setups, and catalysts nowtc pixel

Analysts' Upgrades

All Upgrades
EPM Evolution Petroleum
Northland Securities
Market Perform → Outperform
PT $4.00
9.9% upside
MRNA Moderna
Argus
Hold → Buy
PT $180.00
30.4% upside

Here’s Why Trump Won’t End The Iran War

Sponsored · Partner Content

Here’s Why Trump Won’t End The Iran War

Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.

Uncover the real reason Trump may never end this wartc pixel
I paid $5,000 to hear Elon say this

Sponsored · Partner Content

I paid $5,000 to hear Elon say this

I paid 5,000 dollars to sit in a room with Elon Musk in Los Angeles. What he revealed could be tied to his biggest move yet. I'm sharing the full story and the ticker connected to this launch, free of charge.

Get the full story and ticker details heretc pixel

Analysts' New Coverage

All Initiations
CV CapsoVision
Roth Capital
Buy
PT $9.00
51.8% upside
OSG Octave Specialty Group
Keefe, Bruyette & Woods
Outperform
PT $8.00
73.5% upside
TMC TMC the metals
Stifel Nicolaus
Buy
PT $10.00
107.9% upside

ALERT: Drop these 5 stocks before the market opens tomorrow!

Sponsored · Partner Content

ALERT: Drop these 5 stocks before the market opens tomorrow!

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds…

See the 5 stocks to avoidtc pixel
The Idea Engine™

Fresh stock ideas every week

The Idea Engine™ uses news and technical signals to surface new stock ideas every week, sent straight to your inbox with MarketBeat All Access.

Get MarketBeat All Access

More Stories

Could Falling Yields Make REIT Stocks Worth a Second Look?

Could Falling Yields Make REIT Stocks Worth a Second Look?

By Chris Markoch

Alphabet Is Building a Base—Could a Breakout Be Next?

Alphabet Is Building a Base—Could a Breakout Be Next?

By Ryan Hasson

This Will Change Everything. Get Ready For the Global Power Reset.

This Will Change Everything. Get Ready For the Global Power Reset.

Just Updated

The Stock Screeners Just Got Better

We rebuilt MarketBeat's stock screeners with faster filtering across 75+ criteria to help you find your next investment idea. Take the new experience for a spin.

Try the New Screeners
Thank you for subscribing to MarketBeat!
MarketBeat empowers investors to make better investment decisions by providing up-to-the-minute financial information and independent market research.
 
If you need help with your account, feel free to email our U.S. based support team at contact@marketbeat.com.
 
If you want to opt out or modify which emails you subscribe to, you may modify your email preferences or unsubscribe from this newsletter.
 
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. United States..
 
Featured Link: BioStem Technologies Lands on Nasdaq With Expanding Hospital Reach (From Huge Alerts)